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Toward a Better Understanding of...
Technology for Drug Development 
to Eradicate HIV/AIDS
Rahul Oza
Mentor: Alexander Barnes
Worldwide 36.9 million people live with HIV; 2.6 million are children under the age of 
15. There is still no cure for HIV, but effective treatment with antiretroviral drugs can 
control the virus so that patients with HIV reduce the risk of virus transmission while 
enjoying healthy lives. Our laboratory seeks to design targeted drugs that reverse HIV 
latency; enabling the immune system to identify and destroy HIV-infected cells.  One 
promising therapeutic strategy is to activate the latent reservoirs of HIV within infected 
T-cells. The viral production will directly induce cell death, leading to the eradication of 
HIV/AIDS within patients.
To achieve this goal, we are developing bryostatin, a powerful activator of Protein 
Kinase C (PKC), as a method to reverse HIV latency. PKC activation is a common 
pathway that upregulates HIV expression. Bryostatin 1, a specific PKC activator, 
increases virus production. Viral reactivation performed in combination with HAART, 
which suppresses HIV replication, would help eradicate latent viral reservoirs while 
simultaneously depleting the active virus, essentially curing infected patients.
The goal of this research is to enhance a NMR DNP probe to increase the sensitivity 
and resolution of our solid-state NMR experiments in order to enhance our ability to 
design derivatives of Bryostatin that more effectively activate HIV. A drastic gain in 
sensitivity will allow us to determine biomolecular structure of molecules, such as PKC, 
with less than a milligram of sample. Through enhanced visualization of the biomolecular 
structure of PKC, we will be able to develop better Bryostatin analogs that can selectively 
activate different pathways downstream of PKC known to drive HIV activation, allowing 
us to more effectively reverse HIV latency and thus help rid patients of HIV.
